2026 BTS‑BCS Joint Guideline: Risk‑Stratification & Non‑Invasive Cardiac Testing in Asymptomatic Adult Kidney‑Transplant Candidates

Full title: Joint BTS‑BCS Guideline for Cardiovascular Assessment of Potential Adult Kidney‑Transplant Recipients: Risk‑Stratification and Non‑Invasive Cardiac Evaluation in Asymptomatic Subjects Issuing bodies: British Transplantation Society (BTS) + British Cardiovascular Society (BCS) (April 2026) Evidence‑grading: 1A‑1B = strong‑recommendation；1C‑1D = moderate；2C‑2D = conditional/expert‑opinion；core‑trial‑evidence base: ISCHEMIA‑CKD study

Abstract

Cardiovascular disease is the leading cause of premature death among wait‑listed kidney‑transplant candidates. Historically many transplant centres applied blanket‑routine stress‑testing for all asymptomatic ESRD candidates regardless of exercise capacity and risk‑profile. This 2026 joint‑guideline implements individualised risk‑stratification: routine universal non‑invasive‑stress‑testing is not recommended for all‑comer asymptomatic candidates. Testing is reserved for selected intermediate‑to‑high‑risk subgroups with impaired functional capacity or multiple cardiac‑risk‑factors. Decisions must integrate frailty, exercise‑tolerance, comorbid burden and shared‑patient‑decision‑making, and every abnormal‑positive‑non‑in‑vasive‑result must be reviewed within transplant‑cardiology multidisciplinary‑team (MDT) meetingsBritish Tr....

Keywords: asymptomatic kidney‑transplant‑candidate; ESRD; risk‑stratification; non‑in‑vasive‑cardiac‑testing; stress‑echocardiography; myocardial‑perfusion‑imaging; multidisciplinary‑team; pre‑transplant‑cardiac‑screening

1. Core‑Guiding‑Principles

1. Presumption of transplant‑fitness as starting‑point; cardiac‑tests are for risk‑counselling rather than to arbitrarily exclude patients from listing British Tr...[2D]. 2. No test alone should deny transplant‑listing. All‑test‑results must be interpreted together with frailty, functional‑status, life‑expectancy and patient‑preferences British Tr...[2D]. 3. Avoid over‑screening: over‑investigation may lead to unnecessary invasive‑angiography, contrast‑AKI, procedural‑complications and delayed‑transplant‑access. 4. Multidisciplinary‑team (transplant‑nephrologist, renal‑cardiologist, imaging‑specialist, transplant‑coordinator) review is mandatory whenever advanced‑non‑in‑vasive‑testing yields abnormal‑findings British Tr...[2C]. 5. This guideline applies strictly to asymptomatic candidates without angina‑equivalent symptoms. Symptomatic patients follow separate symptomatic‑CAD‑pathways.

2. Baseline mandatory‑initial‑work‑up (all asymptomatic candidates)

Mandatory for every adult potential kidney‑transplant recipient before risk‑stratification British Tr...[1D] 1. Full‑cardiovascular‑history: prior‑CAD, MI, heart‑failure, PVD/CVD, diabetes‑duration, smoking‑history, dyslipidaemia, dialysis‑vintage. 2. Functional‑capacity‑assessment: estimate exercise‑tolerance (metabolic‑equivalents METs; Duke‑Activity‑Status‑Index‑DASI‑score preferred). 3. 12‑lead resting‑ECG (mandatory for all) British Tr...[1D]. - Significant‑ECG‑abnormalities: Q‑waves, ischaemic‑ST‑T‑persistent‑changes, LV‑hypertrophy‑with‑strain‑pattern, complex‑ventricular‑ectopy. 4. Transthoracic‑echocardiogram (TTE) British Tr...[2C] - May omit TTE only if all‑of‑these are satisfied: normal‑resting‑ECG, no‑cardiac‑murmurs‑on‑auscultation, no‑known‑cardiac‑history, excellent‑exercise‑capacity ≥ 4 METs British Tr...[2C]. - Perform echo on non‑dialysis‑days for haemodialysis‑patients to minimise volume‑overload‑related artefacts. - Echo‑report‑must‑document: LVEF, regional‑wall‑motion‑abnormalities (RWMA), significant‑valvular‑lesions, pulmonary‑arterial‑pressure‑estimation, pericardial‑disease.

3. Three‑tier risk‑stratification (asymptomatic candidates)

3.1 Low‑risk stratum → no‑further‑non‑in‑vasive‑stress‑testing [2C]

Criteria (all must be met): - Asymptomatic; exercise‑capacity ≥ 4 METs (good functional‑status) - Normal‑or‑non‑significant‑rest‑ECG - TTE: LVEF ≥ 50 %, no‑regional‑wall‑motion‑abnormalities; no‑severe‑valvular‑heart‑disease - Absence of high‑risk‑features: no‑insulin‑dependent‑diabetes‑mellitus; no‑history‑of‑PVD/stroke/TIA; short‑dialysis‑vintage (< 2 years)

Recommendation: Proceed directly to transplant‑listing‑work‑up; no‑routine‑stress‑imaging required. Continue‑guideline‑directed‑medical‑therapy (GDMT)‑risk‑factor‑modification.

3.2 Intermediate‑risk stratum → consider‑non‑in‑vasive‑ischaemia‑testing [2C]

One‑or‑more‑feature‑present: - Exercise‑capacity < 4 METs (poor functional‑tolerance, cannot complete ordinary daily‑activities‑without‑fatigue) - Insulin‑treated‑type‑2‑diabetes‑mellitus - Prolonged dialysis‑duration ≥ 2 years - Past‑history‑of‑peripheral‑arterial‑disease / cerebrovascular‑disease (TIA/stroke) - Echo‑findings: mild‑regional‑wall‑motion‑abnormalities, mild‑valvular‑disease, borderline‑pulmonary‑hypertension

Decision‑rule: Stress‑testing is conditional‑optional, not‑automatic‑mandatory. MDT decides whether stress‑imaging adds meaningful‑information to alter listing‑strategy. If exercise‑capacity remains reasonable and patient preferences favour minimal‑testing: can forgo stress‑test and proceed‑to‑list‑without‑ischaemia‑imaging.

3.3 High‑risk stratum → non‑in‑vasive‑stress‑testing is recommended [1B]

Indicators for high‑risk‑category: - Known‑prior‑coronary‑artery‑disease (previous‑MI, prior‑PCI‑/‑CABG‑history) - Rest‑ECG‑shows pathological‑Q‑waves, persistent‑ischaemic‑ST‑T‑abnormalities - TTE: LVEF 40‑49 % or multiple‑segment‑wall‑motion‑abnormalities - Combination of diabetes + PVD + long‑term‑dialysis‑together.

 After‑positive‑stress‑test in‑high‑risk‑asymptomatic‑candidate: MDT‑meeting‑required to weigh: proceed‑direct‑to‑invasive‑coronary‑angiography versus continue‑optimal‑medical‑therapy without‑angiography. Do NOT automatically escalate to ICA just‑because‑stress‑test‑is‑positive.

4. Valid non‑in‑vasive‑ischaemia‑modality‑choices (guideline‑approved tests)

Only functional‑ischaemia‑driven‑tests are endorsed for transplant‑candidate‑risk‑work‑upBritish Tr...: 1. Stress‑echocardiography (exercise‑or‑pharmacological‑dobutamine‑stress‑echo) [preferred‑first‑line‑modality, 1B] - End‑point‑outcome: new‑or‑worsening‑regional‑wall‑motion‑abnormality‑during‑stress‑indicates‑significant‑inducible‑myocardial‑ischaemia. 2. Myocardial‑perfusion‑imaging (MPI‑SPECT / PET‑myocardial‑perfusion) [1C] - Use‑when‑echo‑windows‑are‑poor‑(e.g. obesity, chronic‑lung‑disease‑precluding‑adequate‑ultrasound‑visualisation).

❌ Not‑recommended‑as‑primary‑screening‑tool: Coronary‑CT‑angiography (CCTA) is not‑endorsed‑as‑routine‑pre‑transplant‑CAD‑screen‑in‑this‑version‑of‑guideline, due‑to‑limited‑valid‑outcome‑data‑in‑ESRD‑populations [2D].

Test‑result‑interpretation‑standards

1. Negative‑stress‑test: no‑new‑stress‑induced‑wall‑motion‑defect / no‑reversible‑perfusion‑defect → proceed‑to‑transplant‑evaluation; no‑coronary‑angiography‑needed. 2. Mild‑inducible‑ischaemia‑(small‑territory‑ischaemia, < 10 %‑myocardium‑at‑risk): optimise‑GDMT‑and‑continue‑transplant‑listing; MDT‑follow‑up, do‑not‑automatically‑go‑to‑ICA. 3. Moderate‑to‑severe‑inducible‑ischaemia‑(large‑territory‑reversible‑defect): MDT‑discussion‑mandatory; consider‑invasive‑coronary‑angiography only‑if‑angiogram‑result‑will‑change‑clinical‑management‑(delay‑listing, pre‑transplant‑revascularisation‑plan, or‑de‑listing‑consideration) [1B].

5. Important‑exclusions & caveats

1. Age‑alone does not‑trigger‑stress‑testing. Advanced‑chronological‑age >65 / >70 years is only one‑risk‑factor; functional‑capacity outweighs‑raw‑age [2C]. 2. Diabetes alone is not an‑absolute‑indication‑for‑stress‑test; exercise‑tolerance‑and‑other‑comorbidities‑must‑be‑co‑assessed. 3. If‑patient cannot achieve adequate‑heart‑rate‑target during‑exercise‑stress‑test: use‑pharmacological‑stress‑protocol (dobutamine‑based). An‑incomplete‑stress‑study cannot‑rule‑out‑significant‑CAD.

6. Post‑test‑management‑pathways

1. Negative‑non‑in‑vasive‑stress‑test: continue‑GDMT‑risk‑factor‑control; enter‑active‑transplant‑waiting‑list. No‑ICA. 2. Mild‑positive‑(small‑territory‑ischaemia): maximise‑medical‑therapy; repeat‑clinical‑cardiac‑review‑in‑6‑12‑months; no‑routine‑ICA. 3. Moderate‑severe‑positive‑stress‑test: MDT‑review. Only if‑MDT‑documents‑that‑angiography‑will‑alter‑management → proceed‑to‑invasive‑coronary‑angiography. Even‑if‑angiography‑shows‑obstructive‑CAD → asymptomatic‑candidates‑do‑not‑automatically‑require‑pre‑transplant‑revascularisation; optimal‑medical‑therapy‑remains‑valid‑strategy [1A].

Critical‑guideline‑statement: Stress‑test‑abnormality ≠ mandatory‑pre‑transplant‑revascularisation. Revascularisation‑thresholds match ordinary‑non‑transplant‑CAD‑patients; do‑not‑lower‑threshold‑only‑to‑qualify‑for‑kidney‑transplant‑listing [1A].

7. Special‑populations‑specific‑remarks

7.1 Pre‑emptive‑transplant‑candidates (no‑prior‑dialysis)

Same‑risk‑stratification‑algorithm‑applies. Complete‑cardiac‑non‑in‑vasive‑work‑up before‑planned‑transplant‑date.

7.2 Frail‑asymptomatic‑older‑adults

Frail‑subjects with‑poor‑mobility: prioritise‑patient‑values‑and‑burden‑of‑testing. If‑life‑expectancy‑is‑limited, avoid‑aggressive‑cardiac‑work‑up‑that‑will‑not‑change‑overall‑outcome. Shared‑decision‑making‑is‑central [2D].

7.3 Already‑listed‑wait‑list‑patients

If‑new‑functional‑decline‑occurs‑after‑listing: re‑assess‑exercise‑capacity, re‑run‑baseline‑ECG‑and‑echo; re‑evaluate‑need‑for‑stress‑imaging‑within‑MDT‑meeting.

8. Evidence‑gaps identified in‑guideline

1. Large‑RCT‑directly‑comparing “selective‑stress‑testing‑versus‑no‑stress‑testing”‑in‑asymptomatic‑ESRD‑transplant‑candidates‑remain‑limited; most‑evidence‑derives‑from‑large‑UK‑national‑observational‑cohorts [2D]. 2. Optimal‑threshold‑of‑ischaemic‑territory‑size‑that‑confers‑net‑benefit‑for‑pre‑transplant‑revascularisation‑remains‑unclear. 3. Head‑to‑head‑comparison‑between‑stress‑echo‑versus‑myocardial‑perfusion‑SPECT‑in‑ESRD‑population‑is‑sparse. 4. Predictive‑biomarkers‑(troponin‑high‑sensitivity, BNP)‑to‑improve‑pre‑test‑probability‑modelling‑still‑under‑validation.

9. Consensus‑take‑home‑summary statements

1. For asymptomatic‑adult‑kidney‑transplant‑candidates, universal‑routine‑non‑in‑vasive‑stress‑testing‑for‑every‑candidate‑is‑not‑recommended British Tr...[2C]. 2. All‑candidates receive baseline‑ECG; transthoracic‑echo‑is‑generally‑recommended‑unless‑low‑risk‑criteria‑fully‑satisfied. 3. Risk‑stratification is built‑upon exercise‑capacity (METs), diabetes‑status, dialysis‑duration, prior‑cardio‑cerebro‑vascular‑disease, echo‑and‑ECG‑findings. 4. Low‑risk‑asymptomatic‑subjects with good‑exercise‑capacity ≥ 4 METs can‑be‑listed‑without‑any‑stress‑imaging. 5. Intermediate‑risk‑group: stress‑testing is optional‑conditional‑MDT‑decision‑rather‑than‑automatic‑order. 6. Only high‑risk‑asymptomatic‑candidates (known‑CAD, significant‑ECG‑/‑echo‑abnormalities) should‑be‑offered‑stress‑imaging. 7. A positive‑non‑in‑vasive‑stress‑test does not automatically‑trigger‑coronary‑angiography. MDT‑must‑document‑that‑angiography‑will‑change‑patient‑management‑before‑proceeding‑to‑ICA. 8. Even‑when‑significant‑ischaemia‑is‑detected‑in‑asymptomatic‑patients: optimal‑medical‑therapy‑is‑valid‑alternative‑instead‑of‑pre‑emptive‑revascularisation. 9. Patient‑preferences, frailty‑and‑overall‑comorbidity‑burden must‑always‑be‑integrated‑into‑cardiac‑risk‑assessment.